Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711176 | 0.82 | LMNA (0.42) | MAPTHTTLMNASMN1; SMN2ALOX12 | |
| SCHEMBL6714778 | 0.77 | KDM1A (0.41) | MAPTALOX12ALDH1A1GAAMAPK1 | |
| SCHEMBL6711285 | 0.75 | MAPT (0.53) | MAPTHTTLMNASMN1; SMN2ALOX12 | |
| SCHEMBL6715174 | 0.74 | MAPT (0.54) | MAPTHTTLMNASMN1; SMN2ALOX12 | |
| SCHEMBL6711131 | 0.74 | MAPT (0.41) | MAPTHTTLMNASMN1; SMN2ALOX12 | |
| SCHEMBL6710775 | 0.71 | MAPT (0.54) | MAPTHTTLMNASMN1; SMN2ALOX12 | |
| SCHEMBL6709631 | 0.69 | MAPT (0.47) | MAPTHTTLMNASMN1; SMN2ALOX12 | |
| SCHEMBL8644544 | 0.68 | CYP3A4 (0.43) | GAA | |
| SCHEMBL7838272 | 0.65 | SIRT2 (0.41) | — | |
| SCHEMBL9239498 | 0.62 | SIRT2 (0.43) | MAPTHTTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | CBR3, CBR1, HCCS | MAPT 4753/4885HTT 4421/4885LMNA 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.